Squarepoint’s ABVC BioPharma ABVC Stock Holding History

Squarepoint’s Portfolio ABVC Stock Details ABVC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,547	Closed	-$10.2K	–	4330
2026 Q1	$10.2K	Buy	+10,547	New	+$17.4K	﹤0.01%	4186
2021 Q4	–	Sell	-1,921	Closed	-$44K	–	3112
2021 Q3	$44K	Buy	+1,921	New	+$54.4K	﹤0.01%	2781

Other funds holding ABVC

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Squarepoint's ABVC Position: Q2 2026 in Review

Squarepoint sold out of ABVC BioPharma (ABVC) in Q2 2026, closing a stake of 10,547 shares — an estimated $10.2K sold.

Squarepoint first reported a position in ABVC in Q3 2021 and held it in 2 quarters. The position peaked at $44K in Q3 2021. 15 funds tracked by Wall St. Rank hold ABVC as of Q2 2026.

Squarepoint reported no remaining ABVC BioPharma position as of Q2 2026 after selling out during the quarter.
Squarepoint sold 10,547 ABVC BioPharma shares in Q2 2026, an estimated $10.2K.
Squarepoint first reported a position in ABVC BioPharma in Q3 2021 and held it in 2 quarters.
Squarepoint's ABVC BioPharma position peaked at $44K in Q3 2021.
15 funds tracked by Wall St. Rank held ABVC BioPharma as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.